What changed in the Feb 10, 2026 IRMD analyst rating by Roth Capital?

Roth Capital maintained a Buy on IRMD and raised the price target to **$120** from **$98** on Feb 10, 2026. The note cited product ramp and revenue outlook as reasons.

How should investors interpret the IRMD analyst rating?

A maintained Buy suggests continued analyst confidence in IRadimed’s growth, not a fresh upgrade. Investors should pair the IRMD analyst rating with financials and execution on product ramps.

Does the new IRMD price target change long-term outlook?

The **$120** target raises expected upside from Roth Capital, but long-term outlook depends on sales execution, margins, and market adoption. Use the IRMD analyst rating as one input among many.

Where can I read the Roth Capital note and recent earnings transcript?

Roth Capital’s note is summarized at [TheFly](https://thefly.com/permalinks/entry.php/id4289616/6663286394/IRMD-iRadimed-price-target-raised-by--at-Roth-Capital-heres-why). The Q4 2025 transcript is on [Seeking Alpha](https://seekingalpha.com/article/4868261-iradimed-corporation-irmd-q4-2025-earn-

Analyst Ratings

Roth Capital Maintains Buy on IRMD (IRadimed Corporation) Feb 2026, PT $120

ByHuzaifa Zahoor February 11, 2026February 11, 2026

Roth Capital on Feb 10, 2026 maintained a Buy call on IRadimed Corporation and raised its price target to $120. The IRMD analyst rating action kept the Buy stance while lifting the target from $98. Investors should note the firm issued the note at 3:36 PM ET the same day. This update matters because it links the analyst view to the company’s recent Q4 2025 results and guidance for a $100 million revenue run rate in 2026. Meyka AI rates IRMD with a grade of A.